All Outputs (6)

Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England (2021)
Journal Article
West, J., Card, T. R., Bishton, M. J., Lanyon, P., Ban, L., Bythell, M., …Crooks, C. J. (2022). Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England. Journal of Internal Medicine, 291(4), 493-504. https://doi.org/10.1111/joim.13432

Background: Haemophagocytic lymphohistiocytosis (HLH) is a rare hyper-inflammatory condition with poor outcomes. Objectives: Few population-based estimates of the incidence and survival in adults exist. We aimed to provide these data for England. Met... Read More about Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England.

Ethnicity and suicide risk: A population-based study from England (2021)
Journal Article
Alothman, D., Fogarty, A., Tyrrell, E., Lewis, S., & Card, T. (2022). Ethnicity and suicide risk: A population-based study from England. Journal of Affective Disorders, 298(Part A), 555-557. https://doi.org/10.1016/j.jad.2021.11.044

Using multiple linked electronic health databases, we conducted a large case-control study in England from 2001 through 2019 to examine the association between ethnicity and suicide risk. Asian, Black and Other ethnic groups had a significantly lower... Read More about Ethnicity and suicide risk: A population-based study from England.

Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Taal, M. W., Aithal, G. P., Zhang, W., …Abhishek, A. (2022). Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. Rheumatology, 61(7), 2783-2791. https://doi.org/10.1093/rheumatology/keab790

OBJECTIVE: To develop and validate a prognostic model for LEF discontinuation with abnormal blood test results. METHODS: Data from the Clinical Practice Research Datalink Gold and Aurum were used for model development and external validation, respect... Read More about Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.

Chest Radiograph Scoring Alone or Combined with Other Risk Scores for Predicting Outcomes in COVID-19 (2021)
Journal Article
Au-Yong, I., Higashi, Y., Giannotti, E., Fogarty, A., Morling, J. R., Grainge, M., …Card, T. (2022). Chest Radiograph Scoring Alone or Combined with Other Risk Scores for Predicting Outcomes in COVID-19. Radiology, 302(2), 460-469. https://doi.org/10.1148/radiol.2021210986

Background Radiographic severity may help predict patient deterioration and outcomes from COVID-19 pneumonia. Purpose To assess the reliability and reproducibility of three chest radiograph reporting systems (radiographic assessment of lung edema [RA... Read More about Chest Radiograph Scoring Alone or Combined with Other Risk Scores for Predicting Outcomes in COVID-19.

Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity (2021)
Journal Article
Innes, H., Crooks, C. J., Aspinall, E., Card, T. R., Hamill, V., Dillon, J., …Morling, J. R. (2022). Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity. Hepatology, 75(2), 369-378. https://doi.org/10.1002/hep.32123

Background and Aims: It is thought that alcohol intake and body mass index (BMI) interact supra-additively to modulate the risk of cirrhosis, but evidence for this phenomenon is limited. We investigated the interrelationship between alcohol and BMI o... Read More about Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.

What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline? (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Zhang, W., Doherty, M., …Abhishek, A. (2021). What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. Rheumatology, 60(12), 5785-5794. https://doi.org/10.1093/rheumatology/keab254

Objectives: To examine incidence of treatment changes due to abnormal blood-test results and, to explore rates of treatment changes due to liver, kidney and haematological blood-test abnormalities in autoimmune rheumatic diseases (AIRD) treated with... Read More about What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?.